LH Stock Analysis: Laboratory of America | NYSE
Diagnostics & Research | NYSE, USA | Market Cap: 23.532m USD | 12M Return: 10.3% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 168M
EPS Trend: 56.9%
Qual. Beats: 2
Rev. Trend: 89.3%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Labcorp Holdings Inc. (NYSE: LH) is a U.S.-based clinical laboratory services company operating through two segments: Diagnostics Laboratories and Biopharma Laboratory Services. The company provides a broad menu of routine and specialty tests, including blood chemistry, urinalysis, blood cell counts, thyroid and PSA tests, sexually transmitted disease panels, vitamin D testing, microbiology cultures, and substance abuse screening. Its specialty testing portfolio covers gene-based and esoteric diagnostics, anatomic pathology and oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, womens health, pharmacogenetics, parentage and donor testing, occupational testing, medical drug monitoring, chronic disease programs, and kidney stone prevention.
Labcorp has increasingly invested in digital and technology-enabled offerings, including digital pathology solutions that support the digitization and centralized review of pathology slides, online and mobile platforms for providers, managed care organizations, ACOs, and patients (covering scheduling, check-in, results access, and account management), as well as a Generative AI-enabled Test Selection tool. The company serves a diverse client base spanning individual patients, third-party payers, Medicare/Medicaid, pharmaceutical and biotechnology firms, medical device and diagnostic companies, and contract research organizations (CROs). It maintains strategic collaborations, including with the Childrens Hospital of Philadelphia to advance pediatric diagnostics and with the Alliance for Clinical Trials in Oncology to support a national colorectal cancer clinical trial.
As one of the largest clinical laboratory operators in the United States, Labcorps business model is anchored in high-volume routine testing combined with higher-margin specialty and esoteric testing, supplemented by biopharma services that support drug discovery, development, and commercialization. The U.S. clinical laboratory industry is heavily influenced by third-party reimbursement from Medicare, Medicaid, and private insurers, while also serving growing direct-pay and consumer-initiated testing channels. The company was founded in 1995 and is headquartered in Burlington, North Carolina.
- Biopharma Lab Services revenue grows on clinical trial demand
- Medicare reimbursement cuts pressure diagnostics segment margins
- Quest Diagnostics competition pressures routine testing market share
| Net Income: 941.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA 0.71 > 1.0 |
| NWC/Revenue: 13.56% < 20% (prev 13.09%; Δ 0.47% < -1%) |
| CFO/TA 0.10 > 3% & CFO 1.81b > Net Income 941.5m |
| Net Debt (7.17b) to EBITDA (2.06b): 3.47 < 3 |
| Current Ratio: 1.73 > 1.5 & < 3 |
| Outstanding Shares: last quarter (82.9m) vs 12m ago -1.66% < -2% |
| Gross Margin: 27.79% > 18% (prev 27.89%; Δ -0.10% > 0.5%) |
| Asset Turnover: 77.10% > 50% (prev 74.86%; Δ 2.24% > 0%) |
| Interest Coverage Ratio: 6.16 > 6 (EBIT TTM 1.38b / Interest Expense TTM 223.2m) |
| A: 0.10 (Total Current Assets 4.56b - Total Current Liabilities 2.64b) / Total Assets 19.1b |
| B: 0.46 (Retained Earnings 8.78b / Total Assets 19.1b) |
| C: 0.07 (EBIT TTM 1.38b / Avg Total Assets 18.3b) |
| D: 0.84 (Book Value of Equity 8.73b / Total Liabilities 10.3b) |
| Altman-Z'' = 3.55 = A |
| DSRI: 1.00 (Receivables 2.45b/2.27b, Revenue 14.1b/13.2b) |
| GMI: 1.00 (GM 27.89% / 27.79%) |
| AQI: 0.99 (AQ_t 0.60 / AQ_t-1 0.61) |
| SGI: 1.07 (Revenue 14.1b / 13.2b) |
| TATA: -0.05 (NI 941.5m - CFO 1.81b) / TA 19.1b) |
| Beneish M = -2.98 (Cap -4..+1) = A |
As of July 11, 2026, the stock is trading at USD 276.81 with a total of 267,704 shares traded. Over the past week, the price has changed by -3.54%, over one month by +3.05%, over three months by +6.38% and over the past year by +10.29%.
Current recommended Stop Loss: 268.20 (which is 3.1% or 1.3 ATR below the current price).
Laboratory of America has received a consensus analysts rating of 4.45. Therefore, it is recommended to buy LH.
- StrongBuy: 13
- Buy: 3
- Hold: 4
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 310.1 | 12% |
P/E Trailing = 25.4415
P/E Forward = 16.0256
P/S = 1.6637
P/B = 2.696
P/EG = 1.2136
Revenue TTM = 14.1b USD
EBIT TTM = 1.38b USD
EBITDA TTM = 2.06b USD
Long Term Debt = 5.83b USD (from longTermDebt, last quarter)
Short Term Debt = 688.2m USD (from shortTermDebt, last quarter)
Debt = 8.15b USD (from shortLongTermDebtTotal, last quarter) + Leases 906.5m
Net Debt = 7.17b USD (calculated: Debt 8.15b - CCE 981.1m)
Enterprise Value = 30.7b USD (23.5b + Debt 8.15b - CCE 981.1m)
Interest Coverage Ratio = 6.16 (Ebit TTM 1.38b / Interest Expense TTM 223.2m)
EV/FCF = 22.18x (Enterprise Value 30.7b / FCF TTM 1.38b)
FCF Yield = 4.51% (FCF TTM 1.38b / Enterprise Value 30.7b)
FCF Margin = 9.78% (FCF TTM 1.38b / Revenue TTM 14.1b)
Net Margin = 6.66% (Net Income TTM 941.5m / Revenue TTM 14.1b)
Gross Margin = 27.79% ((Revenue TTM 14.1b - Cost of Revenue TTM 10.2b) / Revenue TTM)
Gross Margin QoQ = 26.52% (prev 26.18%)
Tobins Q-Ratio = 1.61 (Enterprise Value 30.7b / Total Assets 19.1b)
Interest Expense / Debt = 2.74% (Interest Expense 223.2m / Debt 8.15b)
Taxrate = 18.17% (209.3m / 1.15b)
NOPAT = 1.13b (EBIT 1.38b * (1 - 18.17%))
Current Ratio = 1.73 (Total Current Assets 4.56b / Total Current Liabilities 2.64b)
Debt / Equity = 0.93 (Debt 8.15b / totalStockholderEquity, last quarter 8.73b)
Debt / EBITDA = 3.47 (Net Debt 7.17b / EBITDA 2.06b)
Debt / FCF = 5.18 (Net Debt 7.17b / FCF TTM 1.38b)
Total Stockholder Equity = 8.63b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.13% (Net Income 941.5m / Total Assets 19.1b)
RoE = 10.91% (Net Income TTM 941.5m / Total Stockholder Equity 8.63b)
RoCE = 9.51% (EBIT 1.38b / Capital Employed (Equity 8.63b + L.T.Debt 5.83b))
RoIC = 6.85% (NOPAT 1.13b / Invested Capital 16.4b)
WACC = 5.75% (E(23.5b)/V(31.7b) * Re(6.96%) + D(8.15b)/V(31.7b) * Rd(2.74%) * (1-Tc(0.18)))
Discount Rate = 6.96% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -89.89 | Cagr: -1.05%
[DCF] Terminal Value 77.97% ; FCFF base≈1.29b ; Y1≈1.48b ; Y5≈2.18b
[DCF] Fair Price = 312.4 (EV 32.8b - Net Debt 7.17b = Equity 25.6b / Shares 82.0m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 56.86 | EPS CAGR: 4.23% | SUE: 1.82 | # QB: 2
Revenue Correlation: 89.26 | Revenue CAGR: 5.08% | SUE: 0.70 | # QB: 0
EPS current Quarter (2026-06-30): EPS=4.77 | Chg30d=-0.24% | Revisions=+13% | Analysts=10
EPS next Quarter (2026-09-30): EPS=4.59 | Chg30d=+0.00% | Revisions=-6% | Analysts=10
EPS current Year (2026-12-31): EPS=17.98 | Chg30d=-0.12% | Revisions=+62% | GrowthEPS=+9.4% | GrowthRev=+5.5%
EPS next Year (2027-12-31): EPS=19.44 | Chg30d=-0.01% | Revisions=+22% | GrowthEPS=+8.1% | GrowthRev=+4.8%
[Analyst] Revisions Ratio: +21% (up=22, down=14)